Liquid biopsy genotyping in lung cancer: ready for clinical utility?

Wei-Lun Huang; Yi-Lin Chen; Szu-Chun Yang; Chung-Liang Ho; Fang Wei; David T. Wong; Wu-Chou Su; Chien-Chung Lin

doi:10.18632/oncotarget.14613

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Liquid biopsy genotyping in lung cancer: ready for clinical utility?

Wei-Lun Huang, Yi-Lin Chen, Szu-Chun Yang, Chung-Liang Ho, Fang Wei, David T. Wong, Wu-Chou Su and Chien-Chung Lin _

PDF | HTML | How to cite

Oncotarget. 2017; 8:18590-18608. https://doi.org/10.18632/oncotarget.14613

Metrics: PDF 4233 views | HTML 3610 views | ?

Abstract

Wei-Lun Huang1,*, Yi-Lin Chen2,*, Szu-Chun Yang1,*, Chung-Liang Ho2, Fang Wei3, David T. Wong3, Wu-Chou Su1,4 and Chien-Chung Lin1,4

1 Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

2 Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

3 School of Dentistry, University of California, Los Angeles, CA, USA

4 Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

* These authors have contributed equally to this study

Correspondence to:

Chien-Chung Lin, email:

Wu-Chou Su, email:

Keywords: ctDNA, CTC, EGFR mutation, T790M

Received: August 15, 2016 Accepted: January 04, 2017 Published: January 12, 2017

Abstract

Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its potential to detect driver oncogenes such as epidermal growth factor receptor (EGFR) mutants in lung cancer. This technology is advancing rapidly and is being incorporated into numerous EGFR tyrosine kinase inhibitor (EGFR-TKI) development programs. It appears ready for integration into clinical care. Recent studies have demonstrated that biological fluids such as saliva and urine can also be used for detecting EGFR mutant DNA through application other user-friendly techniques. This review focuses on the clinical application of liquid biopsies to lung cancer genotyping, including EGFR and other targets of genotype-directed therapy and compares multiple platforms used for liquid biopsy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14613

Publication Alerts

Reviews:

Liquid biopsy genotyping in lung cancer: ready for clinical utility?

Abstract